Haemonetics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HAE research report →
Range $119 – $165
Price Chart
About the company
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains.
- CEO
- Christopher A. Simon
- IPO
- 1991
- Employees
- 3,009
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on HAE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.47B
- P/E
- 53.03
- Fwd P/E
- 22.48
- PEG
- -1.56
- P/S
- 3.96
- P/B
- 6.10
- EV/EBITDA
- 22.88
- Div Yield
- 0.00%
- Gross Margin
- 58.83%
- Op Margin
- 18.34%
- Net Margin
- 7.52%
- ROE
- 12.07%
- ROIC
- 8.75%
Latest fiscal year · YoY change
- Revenue
- $1.33B-2.0%
- Gross Profit
- $743.59M-4.5%
- Op Income
- $241.40M
- Net Income
- $97.31M-42.0%
- EPS
- $2.05-38.1%
- OCF Growth
- +61.4%
- FCF Growth
- +82.8%
- 52W High
- $132.00
- 52W Low
- $51.00
- 50D MA
- $114.82
- 200D MA
- $82.37
- Beta
- 0.54
- RSI (14)
- 52
- Avg Volume
- 662.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Haemonetics posted strong Q2 fiscal 2027 results, led by double-digit apheresis growth, and raised full-year revenue guidance while trimming operating margin expansion expectations due to investments and cost pressures tied to the CSL rollout.· November 5, 2026
- Organic revenue grew 10% in Q2 and 8% in the first half; adjusted EPS was $1.35 in Q2 and $2.49 in the first half, both up 6%.
- Apheresis was the standout, with organic growth of 14% in Q2 and 10% in the first half; plasma grew 18% in Q2 and 13% in the first half.
- Management said CSL had minimal contribution in Q2, but the expanded relationship should create a multi-year growth runway; they still excluded incremental second-half plasma collection growth from guidance.
- Gross margin improved to 61.9% in Q2, but adjusted operating margin fell and FY2027 operating margin expansion guidance was cut to 0%-50 basis points from 50-100 basis points.
- Full-year FY2027 organic revenue guidance rose to 6%-9% from 4%-7%, reported revenue guidance to 8%-11% from 5%-8%, and apheresis organic growth guidance was raised to high single digits.
Reported Q2 organic revenue growth was 10%, and first-half organic growth was 8%. Adjusted EPS was $1.35 in Q2 and $2.49 in the first half, both up 6%. Q2 adjusted gross margin increased about 140 basis points year over year to 61.9%, while first-half adjusted gross margin rose about 60 basis points to 61.2%. Q2 adjusted operating expenses were $127.6 million, up 15%, and first-half operating expenses were $253.2 million, up 11%. Q2 adjusted operating margin was 26.3%, down 40 basis points, and first-half adjusted operating margin was 24.9%, down 50 basis points. Operating cash flow rose 40% year over year to $180 million in the first half, and free cash flow rose about 57% to $143 million. The company ended the quarter with about $261 million in cash and estimated net leverage of about 2.5x EBITDA. For FY2027, management now expects organic revenue growth of 6%-9% and reported growth of 8%-11%. Apheresis organic revenue growth guidance was raised to high single digits, while MedSurg organic revenue growth guidance was reaffirmed at mid-single digits. Adjusted operating margin expansion is now expected to be 0%-50 basis points, down from 50-100 basis points previously, and free cash flow conversion is expected to be in excess of 80% of adjusted net income.
Chris Simon framed the quarter as evidence that Haemonetics is entering a stronger growth phase, with broad-based momentum across plasma, Blood Management, and Interventional Technologies. He emphasized that CSL, Persona PLUS, TEG 6s disposables, and recent product and regulatory milestones are extending the company’s runway beyond FY2027. His tone was confident but disciplined: he repeatedly said the company is only including confirmed activity in guidance and is not yet assuming incremental second-half benefits that are not already locked in.
James D'Arecca highlighted improved quality of earnings, with gross margin at 61.9% in Q2 and 61.2% in the first half, supported by portfolio mix and tariff refunds. He said operating margin was pressured by higher personnel costs, performance-based compensation, freight, and investment ahead of growth, which is why FY2027 operating margin expansion guidance was reduced to 0%-50 basis points. Cash generation remained strong, with first-half operating cash flow of $180 million, free cash flow of $143 million, and $261 million in cash at quarter-end; he also noted $100 million of revolver repayments year to date and said elevated capital expenditures should continue over the next two years as CSL-related capacity and device needs ramp.
Most of the Q&A focused on CSL, including how much of the contract is in the FY2027 guide, its margin implications, and whether the ramp is linear or back-half weighted. Management said Q2 had minimal CSL contribution, that the guide includes already completed conversions and formally notified Q3 conversions, and that additional Q4 conversions are not yet in guidance. They also said the full Persona PLUS suite is included in CSL’s rollout. Other questions covered plasma collection trends, with management saying U.S. collections were mid- to high-single digits and OUS collections well into the double digits, plus concerns about whether Persona PLUS could cause temporary collection slowdowns. Management said some customers may use the yield gains to back off collections in the near term, which is one reason they excluded collection growth from guidance. Analysts also pressed on margins and capital allocation; management said near-term costs are transitory, FY2028 should show more leverage, and buybacks remain on the table, but organic growth and CSL execution remain the top priority.
The call showed multiple growth engines working at once: plasma, BMT, and IT all grew, and management raised full-year revenue guidance. Management was also upbeat about CSL, Persona PLUS adoption, and new product launches like PerQseal Elite and PacePro, saying they extend the company’s runway beyond FY2027. Cash generation remained strong, giving Haemonetics flexibility to fund investment while still reducing debt and preserving buyback capacity.
Near-term margin leverage is weaker than previously expected, with operating margin guidance cut and management citing higher freight, performance compensation, and ramp costs ahead of CSL. The company is also not counting on incremental second-half plasma collection growth, and management acknowledged some customers could temporarily reduce collection activity as yield improves. CSL is expected to be a meaningful future driver, but much of the financial benefit appears deferred to fiscal 2028 and beyond rather than the current year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.7%
- Shares Outstanding
- 45.54M
- Float Shares
- 44.93M
of shares held by institutions
343 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HAE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lois FrankelHouse · FL21 | Sell | May 6, 21 | Filing → |
| Lois FrankelHouse · FL21 | Sell | May 7, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jan 25, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 20 | Filing → |
| Lois FrankelHouse · FL21 | Buy | Aug 14, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 19, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 1, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | May 15, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | May 28, 20 | Filing → |
| Lois FrankelHouse · FL21 | Sell | Jun 7, 18 | Filing → |
| Lois FrankelHouse · FL21 | Sell | Jun 14, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.95M | ▲ 44.28K |
| Vanguard Group Inc | 4.76M | ▼ 73.51K |
| Neuberger Berman Group LLC | 3.48M | ▼ 697.67K |
| Vanguard Portfolio Management LLC | 2.50M | ▼ 45.17K |
| Aqr Capital Management LLC | 2.27M | ▼ 1.09M |
| Ariel Investments, LLC | 2.17M | ▲ 112.61K |
| Vanguard Capital Management LLC | 2.05M | ▼ 13.77K |
| State Street Corp | 1.80M | ▼ 19.59K |
| Citadel Advisors LLC | 1.51M | ▲ 1.25M |
| Dimensional Fund Advisors LP | 1.28M | ▼ 305.54K |
| Geode Capital Management, LLC | 1.25M | ▼ 41.35K |
| Ubs Group AG | 1.12M | ▲ 135.79K |
Held by 454 ETFs
Biggest fund positions in HAE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Maunsell Farris Maryanne | other | 433 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 645 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 1,068 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 1,724 |
| Nov 11, 26 | Maunsell Farris Maryanne | sell | 836 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 433 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 645 |
| Nov 11, 26 | Maunsell Farris Maryanne | other | 1,068 |
| Oct 30, 26 | Galvin Roy | other | 146 |
| Jul 24, 26 | Madaus Martin D | other | 2,538 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HAE coverage
Recent articles, reports, and earnings notes.
No research on HAE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HAE report →Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
seekingalpha.com · Nov 20
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
marketbeat.com · Nov 20
Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System
prnewswire.com · Nov 18
Ariel Small Cap Value Q3 2026 Portfolio Activity
seekingalpha.com · Nov 13
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
marketbeat.com · Nov 12
International Markets and Haemonetics (HAE): A Deep Dive for Investors
zacks.com · Nov 9
Haemonetics Q2 Earnings Call Highlights
marketbeat.com · Nov 7
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.